CL Lai, E Gane, YF Liaw, CW Hsu, S … - The New England Journal of Medicine, 2007 - nejm.highwire.org From the University Department of Med- icine, Queen Mary Hospital, Hong Kong
(C.-LL); Middlemore Hospital, Auckland, New Zealand (EG); Chang Gung Memo- rial
Hospital, Chang Gung University Col- lege of Medicine, Taipei, Taiwan ... Cited by 175 - Related articles - BL Direct - All 6 versions
- ►hivandhepatitis.com [PDF] EB Keeffe, DT Dieterich, SHB Han, IM Jacobson … - Clinical Gastroenterology and Hepatology, 2008 - Elsevier Chronic HBV infection is an important public health problem worldwide and in the
United States. A treatment algorithm for the management of this disease,
published previously by a panel of US hepatologists, has been revised on ... Cited by 64 - Related articles - All 81 versions
- ►nih.gov YF Liaw, N Leung, JH Kao, T Piratvisuth, E … - Hepatology International, 2008 - Springer Abstract Large amounts of new data on the natural his- tory and treatment of
chronic hepatitis B virus (HBV) infection have become available since 2005.
These include long-term follow-up studies in large community-based cohorts ... Cited by 50 - Related articles - All 3 versions
- ►journalacs.org YF Liaw, E Gane, N Leung, S Zeuzem, Y Wang … - Gastroenterology, 2009 - Elsevier The therapeutic response to telbivudine was superior to that of lamivudine in
HBeAg-positive (63% vs 48%; P < .001) and HBeAg-negative (78% vs 66%; P = .007)
patients. HBeAg-positive patients given telbivudine also had better ... Cited by 42 - Related articles - All 8 versions
F Zoulim, R Perrillo - Journal of hepatology, 2008 - Elsevier This article summarizes the current state of antiviral therapy of hepatitis B
with special attention given to areas that remain controversial or poorly
defined. Strict adherence to liver association practice guidelines may ... Cited by 32 - Related articles - All 35 versions
V Soriano, M Puoti, M Peters, Y Benhamou, M … - Aids, 2008 - journals.lww.com Among the estimated 36 million persons living with HIV worldwide, nearly 4
million (∼10%) are chronically infected with HBV [5] . The prevalence of
coinfection demonstrates geographical variations, largely due to ... Cited by 34 - Related articles - All 13 versions
H Yatsuji, F Suzuki, H Sezaki, N Akuta, Y … - Journal of Hepatology, 2008 - Elsevier The cumulative probability of viral response was 69% at 12 months, and 81% at 24
months. Multivariate analysis identified baseline HBe antigen status (P =
0.0001), aspartate aminotransferase level (AST) (P = 0.001) and HBV-DNA ... Cited by 21 - Related articles - All 23 versions
A Kau, J Vermehren, C Sarrazin - Journal of hepatology, 2008 - Elsevier Treatment predictors are important tools for the management of therapy in
patients with chronic hepatitis B and C virus (HBV, HCV) infection. In chronic
hepatitis B, several pretreatment parameters have been identified for ... Cited by 19 - Related articles - All 23 versions
S Carrouée-Durantel, D Durantel, B Werle- … - Antiviral Therapy, 2008 - intmedpress.com Background: Adefovir dipivoxil (ADV) has demonstrated activity against wild-type
and lamivudine-resistant hepatitis B virus (HBV). After 1 year of therapy, a
median 3.5–4.0 log10 decrease in viral load is observed. Our aim was to ... Cited by 14 - Related articles - BL Direct - All 4 versions
N Leung, CY Peng, HW Hann, J Sollano, J Lao … - Hepatology, 2009 - interscience.wiley.com This study was undertaken to compare the early antiviral activity and viral
kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e
antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB). ... Cited by 12 - Related articles - All 3 versions
